YTHDC1 Inhibitor

About Transition Bio

Transition Bio is a private, pre-clinical stage biotech company pioneering a novel approach to drug discovery focused on biomolecular condensates. The company's core platform integrates droplet microfluidics technology from Harvard's Weitz Lab with biophysical insights from Cambridge's Knowles Lab, creating a unique data engine to screen and optimize compounds using AI/ML. With a $50 million Series A financing and an active collaboration with Voyager Therapeutics, the company is advancing its internal pipeline, including a lead program targeting YTHDC1 in oncology, while also leveraging its platform for partnered discovery. Its strategy targets historically undruggable proteins involved in neurodegeneration and cancer.

Therapeutic Areas

Other MYC-driven cancers Drugs